Drug-Associated Fever During Infusion Therapy: Clinical Insights and Current Evidence

Abstract

Drug-associated fever during infusion therapy represents a significant yet often under-recognized clinical challenge in hospital and outpatient settings. As infusion therapy continues to expand for a variety of indications from chemotherapy to biologics and antimicrobials the incidence and implications of drug-induced fever warrant careful consideration. This review synthesizes the latest scientific literature and guideline recommendations, examining the epidemiology, pathophysiology, clinical features, risk factors, diagnostic strategies, management principles, and emerging advances. Practical insights for clinicians are provided to optimize patient outcomes and minimize unnecessary interventions.

Introduction

Fever during or following infusion therapy frequently prompts diagnostic evaluation for infection, yet medication-induced fever remains a critical differential diagnosis. Drug-associated fever is defined as a febrile response temporally related to drug administration, resolving with cessation of the offending agent, and not attributable to infection or other identifiable causes. Recognition and management of drug fever are essential to prevent unnecessary diagnostic testing, inappropriate antibiotic use, and interruption of vital therapies. This article aims to provide a comprehensive and current review tailored for clinicians managing patients on infusion therapies, integrating recent research and expert guidance.

Epidemiology / Disease Burden

The true incidence of drug-associated fever in infusion therapy is challenging to quantify, as it is often underdiagnosed or misattributed to infectious causes. Estimates suggest drug fevers account for 3-5% of all adverse drug reactions and up to 10% of fevers in hospitalized patients. Populations at higher risk include oncology and rheumatology patients, as well as those receiving prolonged or complex infusion regimens. The growing utilization of monoclonal antibodies, immunomodulators, and combination chemotherapies has expanded the spectrum of implicated agents, making vigilance increasingly important in contemporary practice.

Pathophysiology

The mechanisms underlying drug-associated fever are diverse and multifactorial. Commonly, these fevers are mediated by immune hypersensitivity reactions, particularly type III (immune complex) and type IV (delayed cell-mediated) responses. Some drugs act as pyrogens by stimulating cytokine release (e.g., interleukin-1, tumor necrosis factor-alpha) from monocytes and macrophages. Others may directly affect thermoregulatory centers in the hypothalamus or provoke infusion reactions involving complement activation. Notably, biological agents and immune checkpoint inhibitors can trigger cytokine release syndromes, complicating the clinical picture. Understanding these mechanisms aids clinicians in anticipating, recognizing, and differentiating drug fevers from infectious or neoplastic processes.

Risk Factors

Several factors increase the likelihood of developing drug-associated fever during infusion therapy. These include the use of high-risk drug classes (such as beta-lactam antibiotics, antineoplastic agents, and biologics), prior history of drug hypersensitivity, rapid infusion rates, and underlying comorbid conditions such as autoimmune disorders or immunosuppression. Polypharmacy, genetic predispositions (e.g., HLA subtypes), and repeated exposure to the same or cross-reactive agents further augment susceptibility. Identifying at-risk patients allows for proactive monitoring and early intervention.

Clinical Features

Drug-associated fever typically presents as an isolated, unexplained elevation in body temperature, often in close temporal proximity to drug administration. Fever patterns may be intermittent or sustained and are frequently unaccompanied by localizing signs of infection. In some cases, associated symptoms such as rash, arthralgia, or eosinophilia may suggest a hypersensitivity syndrome. Severe infusion reactions, including rigors, hypotension, or respiratory distress, may occur with specific agents (e.g., rituximab, infliximab) and require immediate attention. The clinical challenge lies in distinguishing drug fever from infectious complications, particularly in immunocompromised hosts.

Diagnosis

Diagnosis of drug-associated fever is largely one of exclusion. A thorough clinical evaluation is essential to rule out infectious, neoplastic, and autoimmune causes. Key diagnostic steps include detailed temporal correlation of fever onset with drug administration, assessment for alternative sources of infection, and review of concomitant medications. Laboratory findings are nonspecific but may reveal leukocytosis or eosinophilia. Discontinuation of the suspected drug and observation for resolution of fever provide a diagnostic clue; rechallenge is rarely indicated due to safety concerns. In cases where the offending agent is essential, desensitization protocols or alternative formulations may be considered under expert guidance.

Treatment & Management

The cornerstone of management is prompt identification and discontinuation of the suspected drug. Supportive care includes antipyretics and hemodynamic monitoring as clinically indicated. Empiric antibiotics should be reserved for cases with high suspicion or evidence of infection. In select scenarios, particularly with mild reactions and essential therapies, clinicians may opt for cautious reintroduction at reduced doses or with premedication (e.g., corticosteroids, antihistamines). Interdisciplinary collaboration with pharmacy and allergy/immunology teams is recommended for complex cases. Patient education regarding potential recurrence and warning signs is vital to reduce morbidity.

Recent Advances / Emerging Therapies

Recent years have seen advances in the identification of biomarkers (e.g., procalcitonin, IL-6) to aid differentiation between infectious and non-infectious fevers, though their clinical utility remains an area of ongoing research. Novel infusion protocols, including slower titration and pre-infusion prophylaxis, have reduced the incidence and severity of infusion-related fevers with certain biologics and chemotherapeutics. Pharmacogenomic profiling to predict susceptibility to drug hypersensitivity syndromes represents a promising frontier. Additionally, the development of biosimilars and alternative drug formulations may offer safer options for patients with prior adverse reactions.

Guideline Recommendations

International guidelines emphasize the importance of a structured approach to fever during infusion therapy. The Infectious Diseases Society of America (IDSA) and other expert bodies recommend thorough evaluation for infection, especially in neutropenic or immunocompromised patients, but caution against indiscriminate antibiotic use in the absence of supporting evidence. Early recognition of drug fever, careful medication reconciliation, and adherence to institutional protocols for infusion reactions are advocated. Documentation and reporting of adverse drug events contribute to improved pharmacovigilance and patient safety.

Conclusion

Drug-associated fever during infusion therapy is a clinically significant phenomenon that necessitates a high index of suspicion and a methodical diagnostic approach. Prompt recognition prevents unnecessary interventions and allows for the safe continuation or modification of essential therapies. Advances in diagnostic tools, pharmacogenomics, and infusion protocols hold promise for improved patient outcomes. Ongoing education, multidisciplinary collaboration, and adherence to evidence-based guidelines remain cornerstones of optimal management in this evolving landscape.